home / stock / gud:cc / gud:cc news


GUD:CC News and Press, Knight Therapeutics Inc.

Stock Information

Company Name: Knight Therapeutics Inc.
Stock Symbol: GUD:CC
Market: TSXC

Menu

GUD:CC GUD:CC Quote GUD:CC Short GUD:CC News GUD:CC Articles GUD:CC Message Board
Get GUD:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

GUD:CC - Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wh...

GUD:CC - Knight Therapeutics Reports First Quarter 2024 Results

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2024. All currency amounts are in ...

GUD:CC - Expected Canadian Company Earnings on Thursday, May 9th, 2024

Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...

GUD:CC - Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City

MONTREAL, May 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:  GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2024 R...

GUD:CC - Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release,...

GUD:CC - TSX Healthcare in April 2024: The Best Stocks to Buy Right Now

2024-04-16 16:00:00 ET The performance of TSX’s healthcare sector in the last six months has been decent (+16.02%), and it continues to outperform the broader market year to date amid the constant spikes and dips. Emerging healthcare trends, including the adoption of artificial intel...

GUD:CC - Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the ...

GUD:CC - Knight Therapeutics Inc. ranks on The Globe and Mail's fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on Business magazine’s fifth annual Women Lead Here list. This an...

GUD:CC - Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2023. All currency ...

GUD:CC - Expected Canadian Company Earnings on Thursday, March 21st, 2024

Bridgemarq Real Estate Services Inc. Restricted Voting Shares (BRE:CA) is expected to report for quarter end 2023-12-31 Avivagen Inc. (VIV:CA) is expected to report for quarter end 2024-01-31 Andean Precious Metals Corp. (APM:CA) is expected to report $0 for Q4 2023 Aimia Inc. (AIM:CA...

Next 10